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We recently reported that the heparin (Hep) III do-
main of fibronectin contains the H2 cell adhesion site in
repeat III5 which binds activated a4 integrins. We have
now further characterized the heparin and cell binding
activities of this domain. A recombinant fragment con-
taining repeats III4-III5 (FN-III4–5) induced Jurkat cell
adhesion upon integrin activation with Mn21 or TS2/16
monoclonal antibody (anti-b1). Adhesion of Mn21-
treated cells to FN-III4–5 or FN-III5 fragments was in-
hibited by chondroitinase ABC and ACII but not by the
anti-a4 monoclonal antibody HP2/1. In contrast, HP2/1
completely blocked adhesion of TS2/16-treated cells
while chondroitinase had a partial (FN-III4–5) or minor
(FN-III5) effect. Thus, the role of each receptor de-
pended on the stimulus used to activate a4b1. The com-
bination of HP2/1 and chondroitinase at dilutions which
did not inhibit when used individually abolished adhe-
sion of Mn21 or TS2/16-treated cells to both fragments,
indicating a cooperative effect between a4b1 and chon-
droitin sulfate proteoglycans (CSPG). Furthermore, we
have identified a 20-amino acid sequence in III5 (HBP/
III5) which binds heparin and induces cell adhesion via
CSPG exclusively. Although soluble HBP/III5 was a poor
inhibitor, when combined with H2, it abolished adhe-
sion to FN-III4–5 and FN-III5 fragments. These results
establish that adhesion to the Hep III domain involves
the cooperation of activated a4b1 and CSPG and show
that HBP/III5 is a novel heparin and CSPG-binding site
contributing to cell adhesion to this domain.
Fibronectin (Fn)1 is a plasma and extracellular matrix pro-
tein which interacts with other macromolecules and with cells
via specific binding sites present in well defined structural and
functional domains (reviewed in Ref. 1). Fn contains two main
cell adhesion domains located in the central and COOH-termi-
nal regions, respectively. The active sites in the central domain
are RGD in repeat III10 and its synergistic sequence PHSRN in
repeat III9 (Refs. 1 and 2, see Fig. 1). These sites bind mainly
a5b1 integrin although RGD is also a ligand for activated a4b1
(3). The COOH-terminal cell-binding region comprises the ac-
tive sites CS-1 and CS-5 within the alternatively spliced seg-
ment IIICS, as well as H1 (IDAPS) in the high affinity heparin-
binding domain or Hep II (Fig. 1). CS-1, CS-5, and H1 are
ligands for a4b1 integrin (4–9).
Besides the H1 a4b1-binding site, the Hep II domain con-
tains several well characterized sequences which bind heparin
and cell surface proteoglycans (PG) (10–12). One of these se-
quences is WQPPRARITGY (peptide FN-C/H V) (12) which
mediates cell adhesion via PG and promotes focal adhesion
formation (13, 14). There is now extensive evidence showing
that PG may modulate the function of a4b1 and that cell
adhesion to the COOH-terminal region of Fn involves the co-
operation between both types of receptors (11, 15–18). It is also
well established that integrin function can be up-regulated by
external factors including the divalent cation Mn21 and certain
anti-b1 mAbs such as TS2/16 (19). Whether these reagents are
mimicking the effects of physiologic regulators such as PG
remains to be determined.
These previous studies have clearly established an impor-
tant role for the Hep II domain of Fn in the adhesion of many
cell systems including melanoma (11), lymphoid (5, 20), hema-
topoietic precursors (15, 18), and neural crest cells (21). How-
ever, it is now becoming evident that other heparin-binding
regions also contribute to cell adhesion. Fn contains 2–3 addi-
tional heparin-binding domains located at the NH2-terminal
(Hep I) and central (Hep III) part of the molecule (see Fig. 1).
These domains differ in their binding affinity and sensitivity to
divalent cation regulation (22–24). The Hep I domain was
recently shown to induce cell adhesion via interaction with the
a5b1 integrin (25). It is not known if this region also interacts
with cell surface PG, although it binds several uncharacterized
molecules at the cell surface (26).
We have also recently reported that a recombinant fragment
containing the Fn III5 repeat, which is part of the Hep III
domain, mediates lymphoid cell adhesion due to the interaction
of the KLDAPT sequence with a4b1 and a4b7 integrins previ-
ously activated with TS2/16 mAb or Mn21, respectively (27).
Our previous observations therefore reveal a novel function for
this domain and highlight the importance of heparin-binding
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regions for the overall cell binding activity of Fn.
In the present study we have further characterized the hep-
arin and cell binding properties of the Hep III domain of Fn. By
preparing recombinant fragments containing type III repeats
from this region, we show that adhesion of Jurkat T cells to a
fragment containing Fn III4-III5 repeats involves the coopera-
tion of activated a4b1 integrin and chondroitin sulfate (CS) but
not heparan sulfate (HS) PG. We also show that the contribu-
tion of each receptor depends on whether Mn21 or TS2/16 are
used to activate a4b1 and that CSPG is crucial when Mn21 is
the reagent of choice. Furthermore, we have identified a novel
20-amino acid sequence in repeat III5, structurally similar to
FN C/H V, which binds heparin and induces cell adhesion via
CSPG exclusively. These results therefore establish novel in-
teractions that regulate cell adhesion to the Hep III Fn domain.
EXPERIMENTAL PROCEDURES
Fibronectin Fragments and Synthetic Peptides—Recombinant frag-
ments containing type III homology repeats 4–5-6 (FN-III4–5-6), 4–5
(FN-III4–5), 4 (FN-III4), and 5 (FN-III5) were produced by polymerase
chain reaction amplification using UlTma DNA-polymerase (Perkin-
Elmer), cDNA from FN-III1/22–11 clones and appropriate primers as
described previously (27). Polymerase chain reaction products were
cloned into pQE-12 or pQE-3/5 vector using the QIAexpress kit and
expressed in Escherichia coli. All cloned cDNAs were sequenced using
a Sequenase 2.0 DNA sequencing kit (U. S. Biochemicals Corp., Cleve-
land, OH). Fragments were purified by immunoaffinity chromatogra-
phy using the specific mAbs (see below) IST-3 (FN-III4, FN-III4–5, and
FN-III4–6) or IST-4 (FN-III5) conjugated to Sepharose 4B (Pharmacia
Biotech, Uppsala, Sweden). None of the fragments contained a 6xHis
tag. Purity of recombinant fragments was confirmed by SDS-polyacryl-
amide electrophoresis gels (15% acrylamide; see Fig. 1). The recombi-
nant fragment H0, comprising the Hep II domain (repeats III12–14)
and repeat III15 was prepared exactly as described (28).
The synthetic peptides KLDAPT (H2), WTPPRAQITGYRLTVGL-
TRR (HBP/III5), WTPQARPITGYRLTVGLTRR (scrambled HBP/III5
or HP/III5.sc), WTPPRAQITGY (HBP/III5-N11), WTPPRAQITGYRLT
(HBP/III5-N14), YRLTVGLTRR (HBP/III5-C10), and YQLTVGLTRR
(HBP/III5-C10.sc) were synthesized on an automated multiple peptide
synthesizer (AMS 422, ABIMED, Langenfeld, Germany) using stand-
ard solid phase procedures and purified by reverse phase high perform-
ance liquid chromatography. Peptides were covalently conjugated to
keyhole limpet hemocyanin (KLH, Calbiochem-Novabiochem Int., La
Jolla, CA) with glutaraldehyde (29) by mixing KLH and peptide at a
molar ratio of 1:3000 in phosphate-buffered saline. Glutaraldehyde was
added dropwise to the peptide-KLH solution and the mixture incubated
at room temperature for 2 h with gentle stirring; after extensive dialysis
against phosphate-buffered saline, peptide coupling efficiency was de-
termined by amino acid analysis after hydrolysis using a Biochrom 20
analyzer (Pharmacia).
Antibodies and Enzymes—IST-3 and IST-4 mAbs reactive with FN-
III4 and FN-III5 repeats, respectively, were produced as reported (30).
Activating anti-b1 mAb T2/16 (purified Ab) and function blocking an-
ti-a4 HP2/1 (culture supernatant) were generously donated by Dr.
Francisco Sa´nchez-Madrid (Hospital de la Princesa, Madrid, Spain).
Chondroitinase ABC (EC 4.2.2.4) and heparinase III (heparitinase I, EC
4.2.2.8) were purchased from Sigma. Chondroitinase AC II (EC 4.2.2.5)
and heparitinase (a mixture of 95% heparitinase I and 5% heparitinase
II, EC 4.2.2.8) were purchased from Seikagaku America Inc. through
ams Biotechnology (Oxon, United Kingdom).
Cells and Cell Cultures—The human T cell line Jurkat was obtained
from Dr. Margarita Lo´pez-Trascasa (Hospital La Paz, Madrid). Cells
were maintained in RPMI 1640, 10% fetal bovine serum (ICN Pharma-
ceuticals, Costa Mesa, CA), and 24 mg/ml gentamycin (Life Technolo-
gies, Inc., Middlesex, UK).
Cell Adhesion Assays—Flat bottom 8-well strips with N-oxysuccin-
imide amine binding surface (Costar Co., Cambridge, MA) were coated
overnight with recombinant fragments or peptides diluted in 0.1 M
sodium borate, pH 8.5. Adhesion assays were carried out as described
(3, 5, 20) for 3 h at 37 °C; attached cells were stained with toluidine blue
and the absorbance at 620 nm was determined on a Multiskan Bichro-
matic plate reader (Labsystems, Helsinki, Finland). Quantitation of cell
attachment was done using calibration curves as described (31) and
optical density at 620 nm was found to be practically a linear function
of the number of cells attached. Total cellular input was calculated in
these assays by spinning wells with the original number of cell aliquots,
then fixing, staining, and measuring optical density. Integrin activation
was performed by incubating the cells (total volume 250 ml) with 5 ml of
TS2/16 mAb (0.28 mg/ml) in RPMI 1640, 10 mM Hepes, 1% bovine
serum albumin, or 10 mM Tris, 150 mM NaCl, 1% bovine serum albu-
min, 2 mM Mn21, pH 7.2, for 15 min at 37 °C prior to the attachment
assay. For inhibition experiments, cells were incubated in a total vol-
ume of 300 ml, with appropiate dilutions of HP2/1 supernatant (1:5 or
1:50), chondroitinase ABC (0.3 or 1.0 Sigma units/ml), chondroitinase
AC II (1 Seikagaku units/ml), heparinase III (0.3 or 1 Sigma units/ml),
heparitinase (2 Seikagaku milliunits/ml), or synthetic peptides (0.5
mg/ml) for 30 min at 37 °C on a rotary shaker; the cell suspension was
then diluted to 7 3 105 cells/ml and 100 ml were added to each sub-
strate-coated well. The assay was then continued as explained above.
To rule out the possibility of protein degradation by protease contami-
nants present in the enzyme preparations, digestions were performed
in the presence of 2 mM phenylmethylsulfonyl fluoride, 0.36 mM pep-
statin A, 2.5 mg/ml leupeptin, 0.1 mg/ml soybean trypsin inhibitor, and
10 mg/ml aprotinin.
Heparin-Sepharose Affinity Chromatography—Recombinant Fn
fragments were applied to columns containing heparin-Sepharose
(Pharmacia) in 25 mM Tris, 30 mM NaCl, 0.5 mM Na2EDTA, pH 7.4,
buffer. After washing the columns with this buffer, bound fragments
were eluted with a linear gradient ranging from 30 to 450 mM NaCl.
Synthetic peptides (1 mg each) were dissolved in 0.4 ml of 25 mM Tris,
50 mM NaCl, 0.5 mM Na2EDTA, pH 7.6, buffer and incubated with 0.3
ml of heparin-Sepharose matrix for 1 h at room temperature under mild
shaking. Unbound material was determined by reading the absorbance
of the solution at 280 nm after centrifugation. The beads were washed
with the same buffer until the absorbance was zero and bound peptides
were eluted using 25 mM Tris, 500 mM NaCl, 0.5 mM EDTA, pH 7.6,
buffer and monitored by optical density at 280 nm. Further identifica-
tion of the bound material was achieved by amino acid analysis and
mass spectrometry using a REFLEX time-of-flight instrument (Bruker-
Franzen Analytik, Bremen, Germany) operated in the positive mode.
RESULTS
Heparin Binding Characteristics of Recombinant Fragments
Containing Repeats III4–5-6 of Fn—Previous studies have
identified a low affinity heparin/DNA-binding domain (Hep III)
in the central region of Fn (1, 22–24). To further analyze the
binding properties of this domain, we prepared recombinant
fragments spanning Fn repeats III4–6, III4–5, III4, and III5,
respectively (Fig. 1), and tested their ability to bind to heparin-
Sepharose affinity matrices. As shown in Table I, all fragments
bound to heparin but the conditions for elution from the matrix
were different. The FN-III4–5 fragment showed the highest
heparin-binding avidity and bound more strongly than the
larger FN-III4–5-6 fragment. Full activity of FN-III4–5 appar-
ently requires both repeats to be present since recombinant
fragments containing single repeats (FN-III4 and FN-III5)
bound to heparin with lower affinity (Table I).
The FN-III4–5 Fragment Mediates Cell Adhesion by Binding
a4b1 Integrin and CSPG, Role of Each Receptor Depends on the
Stimulus Used to Activate a4b1—We have recently shown that
the FN-III5 fragment mediates cell adhesion via interaction of
the KLDAPT sequence (H2) with activated a4 integrins (27). To
establish a possible correlation between the heparin binding
activity of FN-III4–5 repeats and cell binding, we first tested
whether the FN-III4–5 fragment also mediated cell adhesion.
As shown in Fig. 2, resting Jurkat T cells did not bind to this
fragment; however, upon incubation with 2 mM Mn21 or the
activating anti-b1 mAb TS2/16, cells attached to this fragment
in a dose dependent manner. This suggested the implication of
a b1 integrin as the receptor for FN-III4–5, possibly a4b1
which is the receptor for FN-III5 (27). Since FN-III4–5 bound
heparin with high avidity (Table I), we studied the contribution
of both, a4b1 integrin and cell surface PG for attachment to
this fragment.
For these experiments, Jurkat cells were treated with either
2 mM Mn21 or TS2/16 mAb and then incubated with anti-a4
mAb HP2/1, chondroitinase ABC, heparinase III, or the com-
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bination of mAb and enzymes prior to the attachment assay. As
shown in Fig. 3, the contribution of a4b1 and PG to cell adhe-
sion to FN-III4–5 or FN-III5 fragments was different depend-
ing on whether the cells had been treated with Mn21 or TS2/16.
For cells incubated with Mn21, HP2/1 (1:5 dilution) had little
effect on adhesion to either FN-III4–5 (27% inhibition) or FN-
III5 fragments (8% inhibition). However, treatment with chon-
droitinase ABC (1.0 units/ml) completely inhibited adhesion to
both fragments (92 and 95% inhibition, respectively). Treat-
ment with heparinase III (0.3 or 1 units/ml) or heparitinase (2
milliunits/ml, not shown) had no effect. Since chondroitinase
ABC also degrades dermatan sulfate, we tested the effect of
chondroitinase ACII which is specific for CS. At 1.0 units/ml,
this enzyme inhibited adhesion to FN-III4–5 (91% 6 8.3) and
FN-III5 (93% 6 2.1, mean of four experiments, data not
shown), therefore indicating that the receptors for these frag-
ments were CSPG.
Fig. 3 also shows that further dilutions of HP2/1 (1:50) or
chondroitinase ABC (0.3 unit/ml), used individually, did not
affect adhesion to either fragment (0–3% inhibition) of cells
incubated with Mn21. Interestingly, when both reagents were
combined at these concentrations, they inhibited cell adhesion
to FN-III4–5 (65%) and FN-III5 (98%), thus suggesting a co-
operation between both types of receptors. The residual binding
to FN-III4–5 could not be inhibited under these conditions. As
expected, the combination of HP2/1 (1:50) and heparinase III
had no effect (Fig. 3).
Incubation of Jurkat cells with TS2/16 mAb resulted in a
different pattern of adhesion to both fragments. As shown in
Fig. 3, HP2/1 (1:5 dilution) efficiently inhibited (92%) adhesion
to FN-III4–5 fragment and induced partial inhibition (62%) at
1:50 dilution. Chondroitinase ABC had a minor effect at 0.3
unit/ml (10% inhibition) and produced 60% inhibition at 1.0
unit/ml. Similar results were obtained with chondroitinase
ACII (not shown). As observed for cells treated with Mn21,
treatment with heparinase III (or heparitinase) did not affect
adhesion. The combination of HP2/1 (1:50) and chondroitinase
ABC (0.3 unit/ml) completely inhibited (99%) adhesion to the
FN-III4–5 fragment while the combination of HP2/1 and hepa-
rinase III had no effect (Fig. 3).
The HP2/1 mAb also completely (100%, 1:5 dilution) or par-
tially (45%, 1:50 dilution) inhibited adhesion to FN-III5 as we
had previously reported (27). Chondroitinase ABC (1.0 unit/ml)
had little effect in attachment to this fragment (22% inhibition)
but when combined with 1:50 dilution of HP2/1 mAb, produced
100% inhibition (Fig. 3). Heparinase III, either alone or com-
bined with HP2/1 (1:50 dilution), did not affect adhesion to the
FN-III5 fragment (Fig. 3). To confirm that the heparinase
enzymes were active in our assays, we tested their effect on cell
FIG. 1. A, schematic drawing of the hu-
man Fn molecule showing the three types
of internal homology units with type III
repeats numbered. Shaded regions indi-
cate the alternatively spliced segments
(ED-B, ED-A, IIICS) only present in cer-
tain Fn subunits. The location of relevant
sequences involved in cell adhesion via
integrin or PG receptors, including the
novel site (HBP/III5) reported here is in-
dicated. The heparin-binding domains
(Hep I, II, and III) of Fn are also shown. B,
drawing and SDS-polyacrylamide gel
electrophoresis analysis (15% acrylamide)
of the recombinant fragments prepared
and used in the present study. Numbers
indicate the molecular mass (kDa) of
known standars. (Modified from Moyano
et al. (27)).
TABLE I
Heparin-Sepharose affinity chromatography of recombinant fragments
derived from the Hep III domain of Fn
Fibronectin
fragments
NaCl concentration
required for elution
nM
FN-III4–5-6 220
FN-III4–5 300
FN-III4 150
FN-III5 180
FIG. 2. Adhesion of Jurkat cells to increasing concentrations
of FN-III4–5 fragment. Untreated cells (resting) or cells previously
treated with Mn21 or TS2/16 mAb were incubated for 3 h on wells
coated with the indicated concentrations of FN-III4–5. Attached cells
were quantitated as described under “Experimental Procedures.” Val-
ues are the means of at least three different experiments with varia-
bility of ,10%.
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adhesion to the H0 Fn fragment. H0 contains the Hep II do-
main and interacts with a4b1 integrin, CSPG, and HSPG (11,
28, 32). In results not shown, heparinase III (1 unit/ml) or
heparitinase (2 milliunits/ml) had a minor effect when used
alone but when combined with 1:100 dilution of HP2/1 mAb
(which did not inhibit by itself) they produced .95% inhibition
(mean of three experiments), indicating that the enzymes were
active under the conditions used. Altogether these results in-
dicate that adhesion to FN-III4–5 or FN-III5 fragments in-
volves the cooperation of a4b1 and the glycosaminoglycan
(GAG) chains of CSPG. CSPG play an important role when
a4b1 is activated with Mn21 while this integrin is the major
receptor when activation is induced with TS2/16 mAb.
Identification of a 20-Residue Amino Acid Sequence in Fn
III5 Repeat That Contains Heparin and Cell Binding Activi-
ties—The preceding results indicated that the FN-III4–5 frag-
ment binds heparin and CSPG. To further define the specific
sites(s) involved in these interactions, we compared amino acid
sequences in repeats III4-III5 with previously characterized
heparin or PG-binding sites in Fn. The sequence WTPPRA-
QITGY in III5 was highly homologous to WQPPRARITGY or
FN-C/H V, previously shown to bind heparin and HSPG (12,
13). We therefore prepared several synthetic peptides spanning
the WTPPRAQITGY sequence in III5 (Fig. 4) and tested their
capacity to bind to heparin-Sepharose matrices and to mediate
cell adhesion.
As shown in Fig. 5A, the synthetic peptides WTPPRAQITGY
(HBP/III5-N11) and WTPPRAQITGYRLT (HBP/III5-N14) did
not bind to heparin. However, the 20-residue peptide WTP-
PRAQITGYRLTVGLTRR (HBP/III5) as well as HBP/III5.sc, in
which the sequence PPRAQIT was replaced by PQARPI, bound
heparin very efficiently and .90% of the applied material was
recovered in the 0.5 M NaCl fraction (Fig. 5A). Furthermore,
peptide HBP/III5-C10, containing the C-terminal half of HBP/
III5 (see Fig. 4), retained the heparin binding ability and ap-
proximately 41% of peptide eluted in the bound fraction (Fig.
5A). Substitution of the first arginine of C-10 by glutamine
(peptide HBP/III5-C10.sc, Fig. 4) reduced the amount of bound
peptide to 23% (Fig. 5A). The identity of peptides HBP/III5 and
HBP/III5-C10 as the heparin-bound material was confirmed by
amino acid analyses (not shown) as well as mass spectrometry
analyses (Fig. 5B) of the 0.5 M NaCl eluted fractions. These
results therefore show that the heparin-binding site contained
in HBP/III5 resides in the C-terminal sequence YRLTVGLTRR
and that all three arginine residues appear to be important for
the interaction.
To determine whether the HBP/III5 peptide also mediated
cell adhesion, resting, Mn21-treated, or TS2/16-treated Jurkat
cells were added to wells containing increasing concentrations
of peptide covalently coupled to KLH. As shown in Fig. 6, in all
three cases Jurkat cells attached to HBP/III5 in a dose-depend-
ent manner. Cells also attached similarly to the HBP/III5.sc
peptide but not to the shorter HBP/III5-N11 or HBP/III5-N14,
and attached only minimally (,20%) to HBP/III5-C10 and
HBP/III5-C10.sc peptides (results not shown).
Cell adhesion to HBP/III5 was completely inhibited by chon-
droitinase ABC and ACII (1.0 unit/ml) and by soluble HBP/III5
peptide (0.5 mg/ml), regardless of the stimulus used for activa-
tion, while heparinase III (1 unit/ml), heparitinase (2 milli-
units/ml, not shown), HP2/1 mAb (1:5 dilution) or 0.5 mg/ml of
soluble H2 peptide (see Fig. 4) had no effect (Fig. 7). These
results indicate that the full 20-residue sequence contained in
HBP/III5 is necessary for an efficient adhesion and that adhe-
FIG. 4. Synthetic peptides containing sequences from Fn type
III5 repeat prepared and used in the present study. Sequences
are aligned with the previously identified peptide FN-C/H V (12). The
H2 sequence was recently described as an active site in III5 (27). HBP,
heparin-binding peptide; N or C refer to the NH2- or COOH-terminal
halves of HBP/III5, respectively; sc, scrambled.
FIG. 3. Effect of HP2/1 mAb and PG-degrading enzymes on cell adhesion to FN-III4–5 and FN-III5 fragments. Mn21- or TS2/16-treated
Jurkat cells were preincubated for 30 min with HP2/1 (anti-a4), chondroitinase ABC (Chond.), heparinase III, or mixtures of HP2/1 (1:50 dilution),
and enzymes (0.3 unit/ml chondroitinase, 1 unit/ml heparinase III), and added to wells coated with FN-III4–5 or FN-III5 (38 mg/ml). After 3 h,
attached cells were quantitated. Values represent percentage of control (no inhibitor) and are the means of at least five separate experiments.
Standard deviation is indicated by bars.
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sion to this sequence is exclusively mediated by CSPG.
Functional Role of HBP/III5 and H2 Sites in Cell Adhesion
to FN-III5 and FN-III4–5 Fragments—The preceding results
had identified a novel sequence in Fn III5 repeat, HBP/III5,
which mediates cell adhesion via CSPG. Since III5 contains
another sequence, KLDAPT (peptide H2) which binds activated
a4 integrins (27), we studied whether both sets of interactions
acted in a coordinate manner to produce cell adhesion. The
attachment of Jurkat cells to the previously described H2 pep-
tide was first studied. As shown in Fig. 8, adhesion of Mn21-
treated cells to H2-KLH was completely inhibited by mAb
HP2/1 or soluble H2 peptide while heparinase III had no effect.
Interestingly, chondroitinase ABC and ACII also completely
inhibited adhesion to H2 while soluble HBP/III5 peptide was a
poor inhibitor (20% inhibition). For cells treated with TS2/16
mAb, adhesion to H2 was completely blocked by HP2/1 or
soluble H2 peptide (Fig. 7) in agreement with our previous
report (27), but not by soluble HBP/III5 (22% inhibition). Chon-
droitinases ABC and ACII in this case had little effect (15 and
8% inhibition, respectively) and heparinase III did not inhibit
adhesion. These results suggest that for Mn21-treated cells
there is an interdependence of a4b1 and CSPG receptors for
recognition of the H2 sequence. For TS2/16-treated cells, how-
ever, adhesion is almost exclusively dependent on a4b1
integrin.
To determine the contribution of the CSPG or a4b1-binding
sites to cell attachment to FN-III4–5 or FN-III5 fragments,
Mn21- or TS2/16-treated cells were incubated with soluble
HBP/III5 or H2 peptides prior to the adhesion assay. As shown
in Fig. 9, adhesion to the FN-III5 fragment was clearly depend-
ent on a4b1 interaction with the H2 sequence since soluble H2
peptide almost completely blocked adhesion of Mn21- or TS2/
16-treated cells (90 and 93% inhibition, respectively). Soluble
HBP/III5 peptide had a minor effect (8–15% inhibition) al-
though in combination with H2 increased the inhibition to
100% in both cases.
In the case of FN-III4–5, the HBP/III5 peptide alone pro-
duced a 13% inhibition regardless of the activation stimulus
FIG. 6. Jurkat cell adhesion to increasing concentration of
HBP/III5 peptide. Resting or treated cells (with Mn21 or TS2/16) were
incubated for 3 h on wells coated with the indicated concentrations of
HBP/III5 coupled to KLH. Values are the mean of at least three exper-
iments with variability of ,10%.
FIG. 5. Heparin binding properties of HBP/III5 synthetic peptide and smaller related constructs. A, elution profile from heparin-
Sepharose affinity matrices of the indicated peptides. 0.4-ml fractions were collected and monitored by absorbance at 280 nm. B, mass spectrometry
analysis of the 0.5 M NaCl eluted material from assays corresponding to peptides HBP/III5 and HBP/III5-C10.
CSPG and a4b1 Are Receptors for Fibronectin Hep III Domain 139
 at CSIC - Centro de Investigaciones Biológicas on Septem
ber 11, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
used; the H2 peptide did not inhibit adhesion (in fact it in-
creased it slightly) of Mn21-treated cells but produced 71%
inhibition on TS2/16-activated cells (Fig. 9). Interestingly, the
combination of both peptides effectively inhibited (60%) the
adhesion of Mn21-treated cells and increased the inhibitory
effect of H2 for TS2/16-treated cells to 86% (Fig. 9). The resid-
FIG. 7. Inhibition of cell adhesion to
HBP/III5-KLH by chondroitinase ABC
and chondroitinase ACII. Resting or
treated (with Mn21 or TS2/16) Jurkat
cells were preincubated for 30 min with
HP2/1 (1:5 dilution), chondroitinase ABC
or ACII (1.0 unit/ml), heparinase III (1
unit/ml), or soluble HBP/III5 or H2 pep-
tides (0.5 mg/ml each), and added to wells
previously coated with HBP/III5-KLH (19
mg/ml). Attached cells were quantitated
after 3 h. Values are expressed as per-
centage of control (no inhibitor) and are
the mean of five different experiments.
FIG. 8. Effect of HP2/1, PG-degrad-
ing enzymes, and soluble peptides on
cell adhesion to the H2 peptide. Mn21-
or TS2/16-treated cells were preincubated
for 30 min with the indicated reagents
and added to wells coated with H2-KLH
(19 mg/ml). Attached cells were quanti-
tated after 3 h. Values are expressed as
percentage of control (no inhibitor) and
are the mean of five different experiments.
FIG. 9. Effect of soluble peptides on
cell adhesion to FN-III4–5 and FN-
III5 fragments. Mn21- or TS2/16-treated
Jurkat cells were preincubated for 30 min
with HBP/III5 or H2 peptides (0.5 mg/ml)
and added to wells coated with FN-III4–5
or FN-III5 (38 mg/ml). After 3 h, attached
cells were quantitated. Values are ex-
pressed as percentage of control (no pep-
tide) and are the mean of five different
experiments.
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ual adhesion observed in both conditions could not be inhibited
by these reagents. These results indicate that both sites H2 and
HBP/III5 participate in adhesion to the FN-III4–5 fragment
when a4b1 is activated with Mn21, but H2 is prevalent when
the integrin is activated with TS2/16 mAb.
DISCUSSION
The function of the Hep III domain of Fn has been largely
unknown mainly because proteolytic fragments corresponding
to this region do not bind heparin (or DNA) at physiological salt
concentrations (22–24). We have recently shown that a recom-
binant fragment containing repeat III5, within the Hep III
domain induced cell adhesion via interaction of the H2 site
(KLDAPT) with activated a4 integrins, thus establishing a
novel function for this region of Fn (27).
In this report we have further characterized the heparin and
cell binding activities of this domain. We show that a recombi-
nant fragment containing repeats III4-III5 (FN-III4–5) bound
heparin at physiological NaCl concentrations and with higher
avidity than the larger fragment FN-III4–6 (see Table I). One
possible explanation for this is that the site(s) contained in
repeats III4-III5 is partially cryptic and removal of repeat III6
fully exposes it and increases the avidity of the interaction. Fn
contains several cryptic sites including those involved in self-
association (33) and chemotaxis (34). A recent study has shown
that physical tension (such as that produced by tissue injury)
exposes cryptic sites in the Fn molecule (35), thus confirming
the biological relevance of these “latent” regions. These regions
may also become functional upon proteolytic degradation of Fn
at sites of tissue damage.
The FN-III4–5 fragment also induced cell adhesion and this
involved the cooperation of a4b1 integrin and the GAG chains
of CSPG. Early studies had shown that HSPG binding to frag-
ments containing the Hep II domain was necessary for focal
adhesion and stress fiber formation of fibroblasts attached to
the central cell-binding domain of Fn (36). Other reports have
demonstrated that melanoma cell adhesion to fragments or
peptides from the Hep II domain involves the cooperation of
CSPG and a4b1 integrin (11, 15–18), that CSPG can modulate
the function of a4b1 (11), and that this regulation may be
exerted by direct interaction of CSPG with a4 via a newly
identified functional GAG-CS-binding site in this integrin sub-
unit (17).
Our present results on the Hep III domain are in agreement
with these previous studies on the COOH-terminal region of Fn
and show important differences between cell adhesion to the
Hep II and Hep III Fn domains. First, adhesion to FN-III4–5
and FN-III5 fragments required previous activation of a4b1
with Mn21 or TS2/16. Second and most importantly, the role of
a4b1 and CSPG was clearly dependent on whether a4b1 had
been activated with Mn21 or TS2/16 mAb. We and others have
previously shown that these two agents induce high affinity
forms in a4b1 and it was generally assumed that both lead to
similar activation states (19, 20, 37). However, careful exami-
nation of these previous reports reveals subtle differences with
respect to the effects of Mn21 and TS2/16. For example, Ma-
sumoto and Hemler (37) showed that in cells with constitu-
tively low a4b1 activity, Mn21 stimulated adhesion to CS-1 and
VCAM-1, whereas TS2/16 only induced adhesion to VCAM-1.
We have also reported (20) that TS2/16 was 2–3-fold more
effective than Mn21 in inducing recognition of the Hep II do-
main of Fn by monocytic cells. Likewise, TS2/16 but not Mn21
enhanced the constitutive adhesion of these cells to a Fn frag-
ment containing CS-1 (20).
In this report we clearly demonstrate functional differences
between activation of a4b1 with Mn21 or TS2/16, which results
in a higher dependence of GAG-CSPG in the case of Mn21
treatment. The effect of Mn21 was not due to a charge neutral-
ization of the sulfated chains of GAG since other divalent
cations (Ca21, Mg21, resting conditions) did not induce cell
adhesion. Assuming that a4b1 and CSPG form a complex at
the cell surface, we can postulate that activation with Mn21
results in a partially active a4b1 unable to support adhesion by
itself after disruption of the complex with chondroitinase ABC.
In contrast, TS2/16 would lock the integrin in an active confor-
mation which would no longer require cooperation by CSPG. In
support of this, chondroitinase ABC and chondroitinase ACII
completely inhibited adhesion to the synthetic peptide H2
(which does not bind PG) when a4b1 was activated with Mn21,
but had a minor effect on TS2/16 activation. These results
differ from previous findings on melanoma cells where activa-
tion of a4b1 with either reagent reverted the effect of chon-
droitinase ABC (17). An explanation for this could be a differ-
ent constitutive activity of a4b1 in melanoma and lymphoid
cells (our study) thus implying a different regulation by CSPG.
We have also identified a novel amino acid sequence in Fn
repeat III5, WTPPRAQITGYRLTVGLTRR (named HBP/III5),
which binds heparin and mediates cell adhesion via CSPG.
Although the NH2-terminal half of this sequence is highly
homologous to the previously described WQPPRARITGY or
FN-C/H V located in repeat III14 (12), HBP/III5 required all 20
amino acid residues for full activity and this was partially
retained in the last 10 residues but not in the NH2-terminal
portion of the peptide. This indicates that the sequence require-
ments are different for HBP/III5 and FN-C/H V and that the
three arginine residues of the COOH-terminal portion seem to
be crucial for activity of the former. The nature of the GAG
chains that interact with FN-C/H V and HBP/III5 may also be
different. In our study, HBP/III5 as well as fragments FN-
III4–5 and FN-III5 clearly bound CS but not HSPG. Although
this conclusion is based on the lack of effect of heparinase III or
heparitinase in the adhesion assays, we have confirmed that
these enzymes were active under identical conditions when
tested on a substrate previously known to interact with HSPG
(32, 36). Peptide FN-C/H V, however, was originally shown to
bind only HSPG (13) although phorbol 12-myristate 13-acetate-
treated U937 monocytic cells apparently bind this peptide
through both types of PG (14). It is therefore possible that the
differential use of CS or HS GAG chains for interactions with
Fn depends on the nature of the ligand and/or on the cell type
of study.
Based on the present results we can establish that repeat
III5 contains two closely located active sites, the previously
described H2 which binds activated a4 integrin and HBP/III5
which binds CSPG. Both sites cooperate in mediating cell ad-
hesion to the Hep III domain. Moreover, we have consistently
observed that adhesion to FN-III4–5 (but not to FN-III5) could
not be completely inhibited neither with the combination of
chondroitinase ABC and HP2/1 mAb nor with the mixture of
H2 and HBP/III5 peptides, suggesting that additional active
sites may exist in this fragment. These sites could be located in
repeat III4, however, a recombinant fragment containing only
this repeat (FN-III4) did not mediate adhesion of Jurkat cells
(results not shown). This suggests that additional sites may
require the entire III4-III5 region for activity, a fact that is
essential for the high affinity binding of this domain to heparin
(see Table I).
The physiological significance of the Hep III domain is be-
ginning to be revealed. Besides our previous demonstration of
the cell binding activity of repeat III5 and the results presented
here, other authors have shown that: 1) the region encompass-
ing repeats III1-III7 may regulate Fn matrix formation (38); 2)
a mAb recognizing an epitope in repeat III5 inhibited fibro-
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blast-mediated collagen gel contraction (39), suggesting a role
for this region in interactions with collagen. Although further
work is necessary to completely understand the function of this
domain, it is possible that repeats III4-III5 are involved in the
process of Fn matrix formation by interacting with cells as well
as with other macromolecules. In this regard, it was recently
shown that repeats III12–14 in the Hep II domain participate
in Fn polymerization (40). The III4-III5 region may also con-
stitute an important cell attachment domain for activated leu-
kocytes at inflammatory sites and injured tissues, where pro-
teolytic degradation or conformational changes of Fn take place
physiologically.
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